Perrigo Company
681 articles about Perrigo Company
-
Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference
7/25/2023
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call beginning at 8:30 A.M. (EST).
-
This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act
-
Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive
7/13/2023
Perrigo Company plc announced today that the U.S. Food and Drug Administration (FDA) approved Opill ® , a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages.
-
The regulator on Thursday approved Opill, the first oral contraceptive available in the U.S. without a prescription. Perrigo shares rose 6% in response to the news.
-
Perrigo Appoints Patrick Lockwood-Taylor as President and CEO
6/8/2023
Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced the appointment of industry professional Patrick Lockwood-Taylor as its new President, Chief Executive Officer and member of the Board of Directors, effective June 30, 2023.
-
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE
5/16/2023
Perrigo Company plc today announced that it has received final approval from the U.S. Food and Drug Administration for Nicotine Coated Mint Lozenges, 2 mg and 4 mg over-the-counter (OTC).
-
The joint committee of external experts voted unanimously in favor of Perrigo, finding that the benefits of allowing non-prescription use of the birth control tablet Opill outweigh its risks.
-
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
5/10/2023
Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that the U.S. Food and Drug Administration's Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill®, a progestin-only daily oral contraceptive, available for over-the-counter use outweighs the risks.
-
Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
5/9/2023
Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended April 1, 2023.
-
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
5/9/2023
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products , today announced that Murray S. Kessler has notified the Company of his intent to retire as President and Chief Executive Officer, with a target effective date of July 31, 2023.
-
Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023
4/25/2023
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023.
-
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets
3/1/2023
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter ("OTC") equivalent of Advil® Dual Action Tablets 250 mg/125 mg.
-
Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023
2/14/2023
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its fourth quarter and fiscal year 2022 financial results after the U.S. equity markets close on February 27, 2023.
-
Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula
11/1/2022
Perrigo Company plc announced a $170 million strategic investment to expand and strengthen its U.S. infant formula manufacturing, which is expected to bolster industry capacity, enhance consumer choice and increase access to safe, affordable infant formula for parents and caregivers.
-
Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use
10/26/2022
Perrigo Company plc announced that it has received notification that the U.S. Food and Drug Administration has postponed the joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee, previously planned for November 18, 2022, to discuss the Company's application for Opill® once daily oral contraceptive for OTC use.
-
Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill
7/11/2022
Perrigo Company plc, a leading global provider of Consumer Self-Care Products, announced that HRA Pharma, a Perrigo company, has submitted its application to the United States Food and Drug Administration for the first-ever over-the-counter birth control pill in the United States.
-
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES
5/26/2022
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC).
-
PERRIGO TO PRESENT AT UPCOMING CONSUMER INVESTOR CONFERENCES
5/19/2022
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Credit Suisse HALO Investment Summit held in New York City on Wednesday, May 25th.
-
PERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING
4/4/2022
Perrigo Company plc today announced that it has launched a private offering (the "Offering") of $500 million aggregate principal amount of senior notes due 2030,
-
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY
3/17/2022
Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg).